Discover the intriguing link between Tenascin C levels in the bloodstream and the severity of bronchial asthma, shedding new light on potential biomarkers for this chronic respiratory condition.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Assessment of Tenascin C levels in the serum of patients with bronchial asthma.
Elgendy et al., Egypt J Immunol 2024
PMID: 38224032
Summary of Findings:
The study investigates the potential of Tenascin C (TNC), an extracellular matrix glycoprotein, as a novel biomarker for asthma diagnosis and its correlation with asthma severity. Involving 64 asthma patients and 64 controls, the research measured serum TNC levels using ELISA. The findings revealed that:
- Serum TNC levels were significantly higher in asthma patients compared to controls (p ˂0.001).
- The diagnostic utility of serum TNC showed a sensitivity of 93.75%, specificity of 60.94%, and a negative predictive value of 90.7%.
- There was a significant association between serum TNC levels and asthma severity (p=0.004), with the highest levels in severe cases.
Significance: This study suggests that serum TNC could serve as a reliable biomarker for diagnosing bronchial asthma and predicting its severity, contributing to better disease management.